

General information about company	
Scrip code*	543916
NSE Symbol*	NOTLISTED
MSEI Symbol*	NOTLISTED
ISIN*	INE0GYI01028
Name of company	Hemant Surgical Industries Ltd
Type of company	SME
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	12-11-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	05-11-2025
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Half Yearly
Reporting Quarter	Half yearly
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	
Segment Reporting	Single segment
Description of single segment	Medical Equipment & Supplies
Start date and time of board meeting	12-11-2025 15:15
End date and time of board meeting	12-11-2025 16:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	04-01-2023
Indicate Company website link for updated RPT policy of the Company	https://hemantsurgical.com/investor-relations/codes-policies
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	Yes
No. of times funds raised during the quarter	2
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No
	Not Applicable

Financial Results – Other than Bank				
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
Date of start of reporting period		01-04-2025	01-04-2025	
Date of end of reporting period		30-09-2025	30-09-2025	
Whether results are audited or unaudited		Unaudited	Unaudited	
Nature of report standalone or consolidated		Standalone	Standalone	
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.			
1	Revenue From Operations			
	Revenue from operations	6426.06	6426.06	
	Other income	233.43	233.43	
	Total Income	6659.49	6659.49	
2	Expenses			
(a)	Cost of materials consumed	4188.19	4188.19	
(b)	Purchases of stock-in-trade	0	0	
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	442.08	442.08	
(d)	Employee benefit expense	484.91	484.91	
(e)	Finance costs	195.33	195.33	
(f)	Depreciation and amortisation expense	73.29	73.29	
(g)	Other Expenses			
1	Other Expenses	553.37	553.37	
	Total other expenses	553.37	553.37	
	Total expenses	5937.17	5937.17	
3	Profit before exceptional and extraordinary items and tax	722.32	722.32	
4	Exceptional items	0	0	
5	Profit before extraordinary items and tax	722.32	722.32	
6	Extraordinary items	0	0	
7	Profit before tax	722.32	722.32	
8	Tax Expense			
	Current tax	143.32	143.32	
	Deferred tax	38.47	38.47	
	Total tax expenses	181.79	181.79	
9	Net Profit Loss for the period from continuing operations	540.53	540.53	
10	Profit (loss) from discontinuing operations before tax	0	0	
11	Tax expense of discontinuing operations	0	0	
12	Net profit (loss) from discontinuing operation after tax	0	0	
13	Profit (loss) for period before minority interest	540.53	540.53	
14	Share of profit (loss) of associates			
15	Profit (loss) of minority interest			
16	Net profit (Loss) for the period	540.53	540.53	
17	Details of equity share capital			
	Paid-up equity share capital	1303.84	1303.84	
	Face value of equity share capital	10	10	
	Details of debt securities			
18	Reserves excluding revaluation reserve			
19	Earnings per equity share (for continuing and discontinued operations)			
	Basic earnings (loss) per share from continuing and discontinued operations	5.09	5.09	
	Diluted earnings (loss) per share from continuing and discontinued operations	5.05	5.05	
20	Debt equity ratio			Textual Information(1)

21	Debt service coverage ratio			Textual Information(2)
22	Interest service coverage ratio			Textual Information(3)
23	Disclosure of notes on financial results			

Statement of Asset and Liabilities		
	Particulars	Half Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2025
	Date of end of reporting period	30-09-2025
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone
	Equity and liabilities	
1	Shareholders' funds	
	Share capital	1303.84
	Reserves and surplus	9953.38
	Money received against share warrants	1033.86
	Total shareholders' funds	12291.08
2	Share application money pending allotment	0
3	Deferred government grants	
4	Minority interest	
5	Non-current liabilities	
	Long-term borrowings	1734.53
	Deferred tax liabilities (net)	22.13
	Foreign currency monetary item translation difference liability account	
	Other long-term liabilities	
	Long-term provisions	58.21
	Total non-current liabilities	1814.87
6	Current liabilities	
	Short-term borrowings	3515.83
	Trade Payables	
	(A) Total outstanding dues of micro enterprises and small enterprises	113.26
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	2221.76
	Total Trade payable	2335.02
	Other current liabilities	1007.28
	Short-term provisions	438.29
	Total current liabilities	7296.42
	Total equity and liabilities	21402.37
	Assets	
1	Non-current assets	
(i)	Property, Plant and Equipment and Intangible assets	
	Property, Plant and Equipment	3379.48
	Producing properties	
	Intangible assets	0
	Preproducing properties	
	Property, Plant and Equipment capital work-in-progress	1698.45
	Intangible assets under development or work-in-progress	
	Total Property, Plant and Equipment and Intangible assets	5077.93
(ii)	Non-current investments	343
(v)	Deferred tax assets (net)	
(vi)	Foreign currency monetary item translation difference asset account	
(vii)	Long-term loans and advances	482.31
(viii)	Other non-current assets	156.09
	Total non-current assets	6059.33
2	Current assets	
	Current investments	0
	Inventories	3710.71
	Trade receivables	2703.69
	Cash and cash equivalents	7304.67
	Bank balance other than cash and cash equivalents	0

	Short-term loans and advances	764.33
	Other current assets	859.64
	Total current assets	15343.04
	Total assets	21402.37

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2025	01-04-2025
Date of end of reporting period	30-09-2025	30-09-2025
Whether results are audited or unaudited	Unaudited	Unaudited
Nature of report standalone or consolidated	Standalone	Standalone
1 Segment Revenue		
(net sale/income from each segment should be disclosed)		
Total segment revenue		
Less: Inter segment revenue		
Revenue from operations		
2 Segment Result		
Profit (+) / Loss (-) before tax and interest from each segment		
Total Profit before tax		
i. Finance cost		
ii. Other unallocable expenditure net off unallocable income		
Profit before tax		
3 (Segment Asset - Segment Liabilities)		
Segment Asset		
Total Segment Assets		
Un-allocable Assets		
Net Segment Assets		
4 Segment Liabilities		
Segment Liabilities		
Total Segment Liabilities		
Un-allocable Liabilities		
Net Segment Liabilities		

Cash flow statement - indirect	
Particulars	Half Year ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2025
Date of end of reporting period	30-09-2025
Whether results are audited or unaudited	Unaudited
Nature of report standalone or consolidated	Standalone
1 Statement of cash flows	
Cash flows from used in operating activities	
Profit before extraordinary items and tax	722.32
2 Adjustments for reconcile profit (loss)	
Adjustments to profit (loss)	
Adjustments for finance costs	195.33
Adjustments for depreciation and amortisation expense	73.29
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
Adjustments for unrealised foreign exchange losses gains	0
Adjustments for dividend income	0
Adjustments for share-based payments	0
Other adjustments for which cash effects are investing or financing cash flow	-154.22
Other adjustments to reconcile profit (loss)	4.78
Other adjustments for non-cash items	0
Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
Total adjustments to profit (loss)	119.18
3 Adjustments for working capital	
Adjustments for decrease (increase) in inventories	536.8
Adjustments for decrease (increase) in trade receivables	-672.53
Adjustments for decrease (increase) in other current assets	-50.87
Adjustments for increase (decrease) in trade payables	-1545.72
Adjustments for increase (decrease) in other current liabilities	-53.6
Adjustments for provisions	-122.74
Total adjustments for working capital	-1908.66
Total adjustments for reconcile profit (loss)	-1789.48
Net cash flows from (used in) operations	-1067.16
Dividends received	0
Interest paid	0
Interest received	0
Income taxes paid (refund)	90.94
Other inflows (outflows) of cash	0
Net cash flows from (used in) operating activities before extraordinary items	-1158.1
Proceeds from extraordinary items	0
Payment for extraordinary items	0
Net cash flows from (used in) operating activities	-1158.1
4 Cash flows from used in investing activities	
Cash flows from losing control of subsidiaries or other businesses	0
Cash flows used in obtaining control of subsidiaries or other businesses	0
Other cash receipts from sales of equity or debt instruments of other entities	0
Other cash payments to acquire equity or debt instruments of other entities	0
Other cash receipts from sales of interests in joint ventures	0
Other cash payments to acquire interests in joint ventures	0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
Proceeds from sales of property plant and equipment	715
Purchase of property plant and equipment	582.34
Proceeds from sales of intangible assets	0
Purchase of intangible assets	0

Cash advances and loans made to other parties	0
Cash receipts from repayment of advances and loans made to other parties	0
Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
Dividends received	0
Interest received	45.11
Income taxes paid (refund)	0
Other inflows (outflows) of cash	-82.89
Proceeds from government grants	0
Net cash flows from (used in) investing activities before extraordinary items	94.88
Proceeds from extraordinary items	0
Payment for extraordinary items	0
Net cash flows from (used in) investing activities	94.88
5 Cash flows from used in financing activities	
Proceeds from issuing shares	5451.51
Proceeds from issuing other equity instruments	0
Proceeds from issuing debentures notes bonds etc	0
Proceeds from borrowings	2217.27
Repayments of borrowings	0
Dividends paid	0
Interest paid	195.33
Income taxes paid (refund)	0
Other inflows (outflows) of cash	0
Net cash flows from (used in) financing activities before extraordinary items	7473.45
Proceeds from extraordinary items	0
Payment for extraordinary items	0
Net cash flows from (used in) financing activities	7473.45
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	6410.23
6 Effect of exchange rate changes on cash and cash equivalents	
Effect of exchange rate changes on cash and cash equivalents	0
Net increase (decrease) in cash and cash equivalents	6410.23
Cash and cash equivalents cash flow statement at beginning of period	894.44
Cash and cash equivalents cash flow statement at end of period	7304.67

Format for Disclosure of Related Party Transactions (applicable only for half-

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary							
1	Hemant Surgical Industries Ltd	AAACH2620J	Hanskumar Shamji Shah	AAIPPS0147A	Managing Director	Remuneration			Approved			30
2	Hemant Surgical Industries Ltd	AAACH2620J	Kaushik Hanskumar Shah	BBWPS7665B	CFO & Whole time director	Remuneration			Approved			30
3	Hemant Surgical Industries Ltd	AAACH2620J	Hemant Praful Shah	AAIPPS7621K	Whole time director	Remuneration			Approved			30
4	Hemant Surgical Industries Ltd	AAACH2620J	Neha Hanskumar Shah	BBWPS1834E	Relative of director	Remuneration			Approved			15
5	Hemant Surgical Industries Ltd	AAACH2620J	Neha Hemant Shah	AVZPS0736R	Relative of director	Remuneration			Approved			15
6	Hemant Surgical Industries Ltd	AAACH2620J	Leena Shah	AAPPS6958Q	Relative of director	Remuneration			Approved			4.2
7	Hemant Surgical Industries Ltd	AAACH2620J	Mansi Shah	AQBPM3893L	Relative of director	Remuneration			Approved			6
8	Hemant Surgical Industries Ltd	AAACH2620J	Nehal Vishal Thakkar	BVFPK4501B	Non executive director	Remuneration			Approved			3.7
9	Hemant Surgical Industries Ltd	AAACH2620J	Meenal Patodia	ASZPA9080B	Company Secretary	Remuneration			Approved			1.56
10	Hemant Surgical Industries Ltd	AAACH2620J	Ikigai Services Private Limited	AAGCI0534A	Common directors	Sale of goods or services			Approved			65.46
11	Hemant Surgical Industries Ltd	AAACH2620J	Lifesenz Cancer Research Lab Private Limited	AAECL9376R	Common directors	Any other transaction	Rent received		Approved			1.2
12	Hemant Surgical Industries Ltd	AAACH2620J	Daiso Diagnostic LLP	AAPFD8783Q	Common directors	Loan			Approved			0
13	Hemant Surgical Industries Ltd	AAACH2620J	Hansik Healthcare	AAPFH2535L	Common directors	Sale of goods or services			Approved			23.46
14	Hemant Surgical Industries Ltd	AAACH2620J	Magnet Medical Private Limited	AARCM0904H	Common directors	Sale of goods or services			Approved			89.55
15	Hemant Surgical Industries Ltd	AAACH2620J	Hemant Surgical Kenya Limited	ZZZZZ9999Z	Common directors	Sale of goods or services			Approved			1.78

16	Hemant Surgical Industries Ltd	AAACH2620J	Solar Opto Medic Private Limited	AACCS9931P	Wholly owned subsidiary	Purchase of goods or services			Approved			3.12
17	Hemant Surgical Industries Ltd	AAACH2620J	Hansik Healthcare	AAPFH2535L	Common directors	Purchase of goods or services			Approved			0.02
18	Hemant Surgical Industries Ltd	AAACH2620J	Magnet Medical Private Limited	AARCM0904H	Common directors	Purchase of goods or services			Approved			15.63
19	Hemant Surgical Industries Ltd	AAACH2620J	Hemant Praful Shah	AAIPS7621K	Whole time director	Any other transaction	Rent paid		Approved			0.9
20	Hemant Surgical Industries Ltd	AAACH2620J	Leena Shah	AAPPS6958Q	Relative of director	Any other transaction	Rent paid		Approved			0.9
21	Hemant Surgical Industries Ltd	AAACH2620J	Hanskumar Shamji Shah	AAIPS0147A	Managing Director	Loan			Approved			21.77
22	Hemant Surgical Industries Ltd	AAACH2620J	Hemant Praful Shah	AAIPS7621K	Whole time director	Loan			Approved			45.96
23	Hemant Surgical Industries Ltd	AAACH2620J	Neha Hemant Shah	AVZPS0736R	Relative of director	Loan			Approved			12.98
24	Hemant Surgical Industries Ltd	AAACH2620J	Ikigai Services Private Limited	AAGCI0534A	Common directors	Advance			Approved			2.6
25	Hemant Surgical Industries Ltd	AAACH2620J	Lifesenz Cancer Research Lab Private Limited	AAECL9376R	Common directors	Advance			Approved			5.5
Total value of transaction during the reporting period											426.29	

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)	
Mode of Fund Raising	Public Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	31-05-2023
Amount Raised	2484
Report filed for Quarter ended	30-09-2025
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	NA
Comments of the Audit Committee after review	None
Comments of the auditors, if any	None

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	Public Issue Expenses	Nil	313.88	0	313.88	0	
2	To meet Working Capital Requirement	Nil	1000	0	1000	0	
3	Funding Capital Expenditure towards installation	Nil	751.26	0	751.26	0	
4	General Corporate Purpose	Nil	418.86	0	418.86	0	

Signatory Details

Name of signatory	Hanskumar Shamji Shah
Designation of person	Managing Director
Place	Mumbai
Date	12-11-2025

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (2)	
Mode of Fund Raising	Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	01-08-2025
Amount Raised	6152.71
Report filed for Quarter ended	30-09-2025
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	Not applicable
Comments of the Audit Committee after review	No
Comments of the auditors, if any	No

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	Capital expenditure towards development/setting up of new facilities and expansion of existing manufacturing facilities including strategic acquisition/investment	Nil	5000	0	0	0	
2	Augment working capital needs of the Company and its Subsidiaries	Nil	1500	0	788.43	0	
3	Repayment of debt	Nil	1700	0	0	0	
4	For general corporate purposes	Nil	1054.27	0	754.89	0	

